Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Podcast

Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

The FDA outright refuses to review Moderna’s mRNA-based flu vaccine as CBER director Vinay Prasad’s conduct is scrutinized; Disc Medicine receives an unexpected rejection, which Prasad may also have had a hand in; Compass Pathways posts new late-stage data on its psilocybin-based depression drug; CDC is once again leaderless.

February 18, 2026

1 min read

Heather McKenzie

Illustration showing businessman trying to shoulder a big rock

Career Advice

When Senior Leaders Are Asked To Carry Too Much

With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.

February 18, 2026

5 min read

Michael Pietrack

businessman decides to climb the stairs to the moon

Venture capital

Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook

PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.

February 18, 2026

2 min read

Annalee Armstrong

The car overtake on a curve. Top view. vector

Rare diseases

Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations

Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.

February 18, 2026

3 min read

Annalee Armstrong

Business decisions. Businessman with question mark confused many roads vector

Opinion

Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk

Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized.

February 18, 2026

6 min read

Harris Kaplan

Pictured: Gavel hitting pill bottles with abstract money background

Patents

Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors

An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.

February 18, 2026

4 min read

Shawna Williams

illustration of doubtful man thinks whether to jump to the other side of the mountain, dilemma concept

Rare disease

Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership

Disc Medicine’s leadership tried to express optimism that its rare disease therapy bitopertin can be approved based on a Phase 3 trial set to begin shortly. However, analysts are worried that the protocol was developed with former FDA leaders.

February 17, 2026

3 min read

Annalee Armstrong

Mountain climbing route to peak. Business journey path in progress to peak of success. Climbing road to top. Vector illustration

Psychedelics

Compass’ Psychedelic Shows Durability ‘In Spades’ as Path to FDA Clears

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical Officer Guy Goodwin. By providing 26 weeks’ worth of such data instead of the requested 12, the company is delivering “in spades,” he said.

February 17, 2026

3 min read

Heather McKenzie